Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.…
3 High Growth Stocks With At Least 33% Earnings Growth
Vaxcyte (NASDAQ: PCVX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 507 employees.
The shares were at 55.39 USD on 20 November 2026, up 32.8% over 52 weeks. Its 52-week range is 40.14 USD to 90.75 USD: the price is 39.0% below the high and 38.0% above the low.
Its market capitalisation is 8.77B USD.
Vaxcyte reports return on equity of -28.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 1.07B USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 10 analysts cover the stock; their mean price target of 116.40 USD is 110.1% above the current price. The next earnings report is expected on 23 February 2027.